PracticeUpdate: Dermatology - Winter 2018

CONTENTS 5

COVER 20

RESEARCH Editor’s picks 6 Determinants of Patient Satisfaction in a Dermatology Outpatient Clinic Comment by Eliot N. Mostow MD, MPH 7 Clinical Distinctions Between Neuropathic and Inflammatory Pruritus 8 The Medical Necessity of Comprehensive Patch Testing Comment by Salma F. de la Feld MD, FAAD 10 Toxicological Impact of the Sunscreen Ingredient Oxybenzone/Benzophenone-3 Comment by Robert T. Brodell MD, FAAD 11 Cost-Effectiveness of Skin Cancer Referral and Consultation Using Teledermoscopy in Australia Comment by Robin P. Gehris MD 12 Microbiome Associated With Anti-PD-1 Efficacy in Metastatic Melanoma Patients Comment by Robert L. Modlin MD 14 Prevalence of Contact Allergy to Metals in the European General Population With a Focus on Nickel and Piercings Comment by Christen Maria Mowad MD 15 The 9-Valent HPV Vaccine for Treatment of Squamous Cell Carcinomas Comments by Stephen K. Tyring MD, PhD, Uyen Ngoc Mui MD and Ravi Patel MD 16 Silver Absorption and Toxicity Associated With Silver Wound Dressings in Chronic Wounds Comments by Robert S. Kirsner MD, PhD and Ashish C. Bhatia MD, FAAD 17 Safety and Efficacy of Hydrogen Peroxide Topical Solution in Patients With Seborrheic Keratoses 18 A Biologically Based Approach to Acne and Rosacea Comment by Christine Jaworsky MD 19 Antiandrogen Therapy With Spironolactone for the Treatment of Hidradenitis Suppurativa Comment by Paul G. Hazen MD

Itching to Prescribe the Right Treatment for Scabies: Topical Permethrin or Oral Ivermectin? By Warren R. Heymann MD

CONFERENCE 24 International Investigative Dermatology 2018 Meeting By the PracticeUpdate Editorial Team 24 Secukinumab Reduces

CD4-Positive Th17, As Well As CD8- and CD4-Positive Treg Cells in Patients With Plaque Psoriasis

EXPERT OPINION 20 Itching to Prescribe the Right Treatment for Scabies: Topical Permethrin or Oral Ivermectin? By Warren R. Heymann MD 22 25 Two Topical Preparations Show Promise for Eczema 26 Results of Two Studies Point to Potential Treatments for Alopecia Areata 27 Vitamin C and Its Derivatives Suppress Melanogenesis 28 BLZ-100 (Tozuleristide) Shown to Discriminate Between Subtle Molecular Subtypes of Basal Cell Carcinoma 29 After 52 Weeks, Ixekizumab Is Linked to Consistently Higher Responses Than Ustekinumab Across Patient Subgroups With Moderate to Severe Plaque Psoriasis 30 Neutralization of Interleukin 17 Implicated in Inflammatory Skin Diseases Overall and in Psoriasis Specifically

Time for a Churchillian Approach to Idiopathic Guttate Hypomelanosis? By Warren R. Heymann MD

VOL. 2 • NO. 3 • 2018